leisure time -WSS

leisure time

author：focus 2025-10-02 00:52:12 - browse：21

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

hotspot

WSS

EU fines Illumina $475 million over Grail acquisition

One Duchenne patient's bittersweet hope for new treatment

Virtual Event: March of the Biosimilars

Virtual Event: March of the Biosimilars

U.K. researchers warn about biases in medical devices, algorithms

Methadone treatment changes are coming. Do they go far enough?

entertainment

leisure time

focus

Jerome Adams on the need for new antivirals for Covid

Stop the failed accountable care organization experiment

Medical records are filled with copy

Colonoscopy prep: Liquid

Continuity nursing helped my family in our darkest PICU moments

Companies helping big Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

SCOTUS questions limit to govt efforts to fight misinformation

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Virtual Event: March of the Biosimilars

hotspot

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Digital health funding stays low as a new reality sets in

Physicians and social media: If you see something, say something?

App could help diagnose ear infections more accurately — and at home

Creating egg and sperm cells from stem cells raises ethical issues

hotspot

entertainment

hotspot

explore